Help lung cancer patients choose the best therapy liquid biopsy performance than shoulder tissue biopsy
March 01, 2019 Source: WuXi PharmaTech
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)]; For patients with non-small cell lung cancer (NSCLC), how to choose the best treatment for treatment after initial diagnosis is a problem that is closely related to their prognosis. The medical guidelines suggest that if a patient's tumor mutates in seven genes, EGFR, ALK, ROS1, BRAF, RET, MET, and ERBB2, they should be treated with the appropriate targeted therapy. Because these targeted therapies are usually more effective than chemotherapy or immunotherapy. However, detecting these genetic variants usually requires the patient to undergo a tissue biopsy, meaning that the surgeon needs to take a small piece of tissue from the patient's lungs and then hand it to the tester for testing. This is not only a time-consuming and laborious process, but also a pain to the patient. So is there a blood test that allows patients to learn the same information to help them choose the best treatment? The answer for Guardant Health is that there is! Recently, it announced the results of a head-to-head clinical trial of the Guardant360 blood test and traditional tissue biopsy developed by the company to detect the above-mentioned genetic variants in NSCLC patients. The results of the trial showed that Guardant360 found that the sensitivity of the gene mutation was similar to that of tissue biopsy.
Guardant360 is a liquid biopsy that helps cancer patients choose the best treatment by detecting cell-free DNA (cfDNA) in the blood. Since tumor cells in the body release cfDNA into the blood circulation, the detection of cfDNA can not only obtain the genetic information related to the tumor in a minimally invasive manner, but also increase the speed of obtaining the diagnosis result and reduce the diagnosis cost.
In this clinical trial called NILE, 282 patients with newly diagnosed advanced NSCLC underwent both tissue biopsy and Guardant360 testing. The results of the trial showed that tissue biopsies detected mutations in the above seven genes in 60 (21.3%) patients, while Guardant 360 detected 77 patients (27.3%) carrying such genetic variants. Moreover, Guardant360 can get diagnostic results on average for 9 days, while traditional tissue biopsy takes an average of 15 days to get a diagnosis. It is worth noting that all positive patients found by Guardant360 are also confirmed in tissue biopsies when detecting EGFR, ALK, BRAF, and ROS1 gene variants. These genetic variants have been targeted to FDA-approved therapies, so Guardant360 may provide these patients with information to help select the best therapy earlier and more easily.
"Because this test can detect genetic mutations in proportion to tissue biopsies and can complete patient testing in less time, the first use of liquid biopsy in newly diagnosed advanced NSCLC patients is a powerful option." The study's senior author, Professor Vassiliki Papadimitrakopoulou of the MD Anderson Cancer Center, said.
Reference materials:
[1] Guardant's blood test might replace biopsies for some lung cancer patients, study says. Retrieved February 28, 2019, from https:// /
[2] Head-to-Head Comparison to be Presented at AACR Supports Use of "Blood First" For First-Line Advanced NSCLC Patients. Retrieved February 28, 2019, from https://guardanthealth.gcs-web.com/news- Releases/news-release-details/guardant360-performance-matches-standard-care-tissue-testing
Wirelless Fire Alarm System,Wireless Fire Sounder,Wireless Fire Detection,Wireless Smoke Detector
LIAONING YINGKOU TIANCHENG FIRE PROTECTION EQUIPMENT CO.,LTD , https://www.tcfiretech.com